quinazolines has been researched along with azd 6244 in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 24 (88.89) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Ikezoe, T; Koeffler, HP; Komatsu, N; Kuwayama, Y; Nishioka, C; Taguchi, H; Takeshita, A; Tasaka, T; Togitani, K; Yang, J; Yang, Y | 1 |
| Bang, YJ; Han, SW; Hur, HS; Im, SA; Kim, HP; Kim, TY; Oh, DY; Yoon, YK | 1 |
| Chung, YH; Kim, KH; Kim, KM; Lee, D; Lee, HC; Lee, SG; Lee, YJ; Lee, YS; Lim, YS; Park, YK; Shim, JH; Suh, DJ | 1 |
| Friedrich, MJ | 1 |
| Bareford, MD; Cruickshanks, N; Dai, Y; Dent, P; Grant, S; Hamed, HA; Hubbard, N; Mitchell, C; Tang, Y; Tye, G; Yacoub, A | 1 |
| Akar, U; Bartholomeusz, C; Esteva, FJ; Kazansky, A; Kigawa, J; Kondo, K; Krishnamurthy, S; Lee, J; Liu, P; Oishi, T; Saso, H; Ueno, NT | 1 |
| Bekele, BN; Biernacka, A; Erez, B; Herbst, RS; Hosho, K; Jacoby, JJ; Jürgensmeier, JM; Komaki, R; Korshunova, MV; O'Reilly, MS; Ryan, A; Smith, PD; Takahashi, O; Wistuba, II | 1 |
| Arozarena, I; Ehrhardt, M; Ferguson, J; Wellbrock, C | 1 |
| Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW | 1 |
| Chan, AT; Cheng, SH; Cheung, CS; Ho, K; Hui, EP; Lau, CP; Lui, VW; Ma, BB; Ng, MH; Ng, PK; Tsao, SW; Tsui, SK | 1 |
| Chang, YJ; Huang, MH; Lee, JH; Lin, AM; Lin, YL; Tsai, HH; Yang, JC | 1 |
| Buss, MC; Castellino, RC; Gayle, SS; Nahta, R | 1 |
| Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Chen, JQ; Giaccone, G; Goldsmith, PK; Heldman, MR; Herrmann, MA; Lee, JH; Park, KS; Wang, Y | 1 |
| Cho, SY; Choi, J; Hwang, JJ; Jang, SJ; Kim, CS; Lee, G; Lee, JH; Lee, SW; Lim, C; Seo, J; Song, JY | 1 |
| El Touny, LH; Green, JE; Hoenerhoff, MJ; Khanna, C; Mendoza, A; Vieira, A | 1 |
| Baumann, M; Benes, CH; Chowdhury, D; Efstathiou, JA; Greninger, P; Hülskötter, M; Kern, AM; Krause, M; Pan, Y; Settleman, J; Singh, A; Wang, M; Willers, H | 1 |
| Li, H; Ma, D; Qu, Y; Wu, X; Yang, Y; Yin, Y | 1 |
| Alagesan, B; Bardeesy, N; Benes, CH; Contino, G; Corcoran, RB; Deshpande, V; Engelman, J; Guimaraes, AR; Hezel, AF; Loda, M; Weissleder, R; Wojtkiewicz, GR; Wong, KK | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Bevilacqua, S; D'Alessio, A; De Luca, A; Gallo, M; Maiello, MR; Normanno, N | 1 |
| Bokobza, SM; Devery, AM; Jiang, Y; Ryan, AJ; Wadekar, R; Weber, AM | 1 |
| Chen, L; Cheng, L; Jin, Y; Liu, M; Ruan, M | 1 |
| Lim, SY; Menzies, AM; Rizos, H | 1 |
| Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL | 1 |
| Allen, J; Backen, AC; Connell, J; Dive, C; Jackson, A; Jayson, GC; Li, K; Manoharan, P; Marti, FEM; Misra, V; Mistry, H; O'Connor, J; Ortega, F; Renehan, AG; Saunders, MP; Simpson, KL; Stratford, I; Underhill, S; Williams, KJ | 1 |
| Adjei, A; Costello, BA; Doyle, LA; Erlichman, C; Fiskum, J; Haluska, P; Hubbard, JM; Ivy, P; Lin, G; Menefee, M; Qin, R; Reid, JM; Schenk, EL; Strand, C; Yin, J | 1 |
1 review(s) available for quinazolines and azd 6244
| Article | Year |
|---|---|
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2017 |
3 trial(s) available for quinazolines and azd 6244
| Article | Year |
|---|---|
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Chemoradiotherapy; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Rectal Neoplasms; Tissue Distribution | 2019 |
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Quinazolines; Vascular Endothelial Growth Factors | 2022 |
23 other study(ies) available for quinazolines and azd 6244
| Article | Year |
|---|---|
ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Proliferation; Drug Synergism; Humans; Leukemia; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Piperidines; Quinazolines; Tumor Cells, Cultured | 2007 |
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; In Situ Nick-End Labeling; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Stomach Neoplasms | 2009 |
Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?
Topics: Animals; Antineoplastic Agents; Benzimidazoles; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Trans-Activators; Viral Regulatory and Accessory Proteins | 2011 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Benzimidazoles; Benzodioxoles; Breast Neoplasms; Cell Death; Cell Line, Transformed; Cell Transformation, Neoplastic; Checkpoint Kinase 1; Dasatinib; Female; Fibroblasts; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Protease Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-fyn; Proto-Oncogene Proteins c-yes; Pyrimidines; Quinazolines; Radiation Tolerance; src-Family Kinases; Thiazoles | 2011 |
MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Topics: Adenocarcinoma, Clear Cell; Animals; Apoptosis Regulatory Proteins; Benzimidazoles; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Ovarian Neoplasms; Phosphoproteins; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2012 |
Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.
Topics: Benzimidazoles; Benzodioxoles; Cell Adhesion; Cell Division; Collagen; Humans; Integrin beta1; MAP Kinase Kinase Kinases; Melanoma; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2013 |
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Docetaxel; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Experimental; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Taxoids; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Synergism; Gefitinib; Humans; Mitogen-Activated Protein Kinase Kinases; Nasopharyngeal Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines | 2013 |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
Topics: Animals; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; GTP Phosphohydrolases; Humans; Lung Neoplasms; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2013 |
MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast; Breast Neoplasms; Cell Line, Tumor; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines | 2013 |
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Docetaxel; Erlotinib Hydrochloride; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2013 |
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Immunoassay; Lung Neoplasms; Lymphatic Metastasis; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasms, Experimental; Oncogene Proteins; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyridones; Quinazolines; Sulfonamides | 2013 |
Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Knockdown Techniques; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Neoplasm Recurrence, Local; Quinazolines; RNA, Small Interfering; src-Family Kinases; Xenograft Model Antitumor Assays | 2014 |
EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.
Topics: Animals; Apoptosis; Aurora Kinase B; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Chromatin; DNA Breaks, Double-Stranded; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase C-alpha; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiation Tolerance; ras Proteins; Xenograft Model Antitumor Assays | 2014 |
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Topics: Animals; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gefitinib; Humans; Imidazoles; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Humans; MAP Kinase Kinase Kinases; Mice, Transgenic; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines | 2015 |
EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Topics: Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Triple Negative Breast Neoplasms | 2015 |
Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Topics: Benzimidazoles; Blotting, Western; Carcinoma, Papillary; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Imidazoles; Inhibitory Concentration 50; Lapatinib; MAP Kinase Kinase 1; Microscopy, Fluorescence; Mutation, Missense; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms | 2017 |
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome | 2017 |